Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: protein kinase inhibitors - Qurient Therapeutics

Drug Profile

Research programme: protein kinase inhibitors - Qurient Therapeutics

Alternative Names: Axl kinase inhibitors - Qurient Therapeutics; CDK7 inhibitors - Qurient Therapeutics; CSF1R inhibitors; Cyclin-dependent kinase 7 inhibitors - Qurient Therapeutics; Mer kinase inhibitors - Qurient Therapeutics; Q-701

Latest Information Update: 07 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Planck Innovation; The Lead Discovery Center; The Max Planck Institute of Biochemistry; Vichem Chemie
  • Developer Max Planck Innovation; Qurient Co; The Lead Discovery Center
  • Class Anti-inflammatories; Antineoplastics; Antivirals
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Discontinued Inflammation; Viral infections

Most Recent Events

  • 07 Jun 2022 Preclinical trials in Solid tumours in South Korea (PO) (Vichem Chemie pipeline, June 2022)
  • 24 May 2019 Discontinued for Inflammation in South Korea (unspecified route) (Qurient Therapeutics pipeline, May 2019)
  • 24 May 2019 Discontinued for Viral infections in South Korea (unspecified route) (Qurient Therapeutics pipeline, May 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top